ERBB2 and breast cancer: have found that FASN induces resistance to multiple DNA-damaging agents including DOX and cisplatin without impacting sensitivity to microtubule agents or antimetabolites whereas Menendez JA et al. have found that the inhibition of FASN activity strengthens the cytotoxicity of docetaxel in the HER2-overexpressing breast cancer cell lines (170, 171).